BBIO vs NVS

For growth investors, BridgeBio Pharma, Inc.

(BBIO) is the stronger pick with 126. 3% revenue growth year-over-year, versus 6. 0% for Novartis AG (NVS). Novartis AG (NVS) offers the better valuation at 20. 6x trailing P/E (16. 9x forward), making it the more compelling value choice. Analysts rate BridgeBio Pharma, Inc. (BBIO) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +99.

3%, compared to +37. 3% for BridgeBio Pharma, Inc. (BBIO). Over 10 years, the gap is even starker: NVS returned +188. 8% versus BBIO's +147. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.

42β versus BridgeBio Pharma, Inc. 's 1. 23β — meaning BBIO is approximately 189% more volatile than NVS relative to the S&P 500.

By revenue growth (latest reported year), BridgeBio Pharma, Inc.

(BBIO) is pulling ahead at 126. 3% versus 6. 0% for Novartis AG (NVS). On earnings-per-share growth, the picture is similar: Novartis AG grew EPS 22. 5% year-over-year, compared to -31. 6% for BridgeBio Pharma, Inc.. Over a 3-year CAGR, BBIO leads at 86. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus -145. 3% for BridgeBio Pharma, Inc. — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus -113. 3% for BBIO. At the gross margin level — before operating expenses — BBIO leads at 94. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BBIO: 47.

7% to $100. 58.

In this comparison, NVS (2.

7% yield) pays a dividend. BBIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 2. 7% yield, +188. 8% 10Y return). Both have compounded well over 10 years (NVS: +188. 8%, BBIO: +147. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BBIO is a mid-cap high-growth stock; NVS is a large-cap quality compounder stock. NVS pays a dividend while BBIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.